Skip to main content

Table 1 Participants’ characteristics

From: Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue

ID# Clinical diagnosis Pathological diagnosis Age at death (yrs) Gender PMI (hrs) Braak & Braak (NFT) CERAD score (neuritic plaques) NIA-Reagan Institute criteria
#1 CTL Normal adult brain 86 M 10 I none LP
#2 CTL Normal adult brain 73 F 20 I none LP
#3 CTL Normal adult brain 101 F 22 II A LP
#4 AD AD 96 F 20 V C HP
#5 AD AD 78 F 18 VI C HP
#6 AD AD 97 F 12 VI A HP
#7 AD AD 87 F 12 IV B IP
#8 AD AD 60 M 24 VI C HP
#9 AD AD 82 F 6 V B HP
#10 AD AD 69 F 4 VI C HP
#11 AD AD 70 M 6 V C HP
#12 AD AD 66 F 2 VI C HP
#13 AD AD 66 F 10 VI C HP
#14 AD AD 97 F 24 V C HP
#15 AD AD 81 M 7 IV C IP
#16 FTLD AD/CAA 66 M 16 V B HP
#17 Memory, speech and gait difficulties, hand tremor Diffuse CAA (D23N Iowa APP mutation) 45 M N/A I none LP
#18 AD AD/Metastatic melanoma 75 M 35 V B IP
#19 FTLD PiD, type A 61 M 19 N/A N/A N/A
#20 FTLD PiD 62 M 19 I A LP
#21 FTLD (P301L Mutation) FTLD 71 F 4 I none LP
#22 FTLD DLDH 65 M 24 I none LP
#23 CBD CBD 80 M 6 I none LP
#24 PSP PSP 69 M 45 II none LP
#25 PSP PSP 68 M 48 II none LP
#26 PSP PSP 78 M 11 II none LP
#27 PSP PSP 73 M 12 II none LP
#28 PSP PSP 63 F 12 II none LP
#29 CTE CTE (CTE stage II-III) [23] 25 M 27 0 none LP
#30 CTE CTE (CTE stage III) 56 M N/A II none LP
#31 CTE CTE (CTE stage III) 46 M 72 III none LP
#32 CTE CTE (CTE stage IV) 65 M N/A II A LP
#33 CTE CTE (CTE stage III) 58 M N/A III none LP
#34 DLB LBD 62 M 24 N/A none N/A
#35 DLB LBD, brainstem predominant 76 M 17 II none LP
#36 PDD LBD (Braak stage 4/6) 83 M 9 III none LP
#37 MSA MSA, cerebellar type (MSA-C) 60 F 32 II none LP
#38 FTLD FTLD-TDP-43, type A 69 F 16 I none LP
#39 FTLD FTLD-TDP-43 55 M 14 I none LP
#40 FTLD FTLD-TDP-43 68 M 49 I none LP
#41 FTLD FTLD-TDP-43 64 M 12 I none LP
#42 Headache Subarachnoid hemorrhage 92 F N/A IV A IP
#43 N/A Parenchymal hemorrhage 75 M N/A I none LP
  1. Abbreviations: AD Alzheimer’s disease, APP amyloid precursor protein, CAA Cerebral amyloid angiopathy, CBD Corticobasal degeneration, CERAD Consortium to establish a registry for Alzheimer’s disease, CTL Control subject, DLB Dementia with lewy bodies, DLDH Dementia lacking distinctive histopathology, F Female, FTLD Frontotemporal lobar degeneration, HP High probability, IP Intermediate probability, LP Low probability, M Male, MSA Multiple systemic atrophy, NFT Neurofibrillary tangles, NIA National Institute of Aging, N/A Non available, PiD Pick’s disease, PMI Postmortem interval, PSP Progressive supranuclear palsy, TDP-43 TAR DNA binding protein 43